PD-1抑制剂联合颅脑放疗治疗NSCLC脑转移的效果  

Effect of PD-1 inhibitor combined with craniocerebral radiotherapy in the treatment of non-small cell lung cancer with brain metastases

作　　者：张聪[1] 郑桂丽 李娜[3] ZHANG Cong;ZHENG Gui-li;LI Na(Department of Radiotherapy,960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Jinan 250031,China;Department of Oncology,960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Jinan 250031,China;Department of Respiratory,960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Jinan 250031,China)

机构地区：[1]中国人民解放军联勤保障部队第九六○医院放疗科,山东济南250031 [2]中国人民解放军联勤保障部队第九六○医院肿瘤科,山东济南250031 [3]中国人民解放军联勤保障部队第九六○医院呼吸科,山东济南250031

出　　处：《哈尔滨医科大学学报》2024年第3期260-264,共5页Journal of Harbin Medical University

基　　金：山东省自然科学基金资助项目(ZR2020MA053)。

摘　　要：目的探讨程序性死亡蛋白1(programmed death protein-1,PD-1)抑制剂联合颅脑放疗治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)合并脑转移的临床效果。方法选取中国人民解放军联勤保障部队第九六〇医院2021年9月~2023年5月收治的68例NSCLC合并脑转移患者,按治疗方法不同分为2组,其中对照组(n=33)采取全身化疗联合颅脑放疗治疗,观察组(n=35)全身化疗联合颅脑放疗加用PD-1抑制剂治疗,两组均治疗4个疗程,比较两组疗效。结果观察组客观缓解率(objective response rate,ORR)较对照组高(P<0.05)。治疗4个疗程,观察组肿瘤标志物水平优于对照组(P<0.05)。两组不良反应发生率比较无显著差异(P>0.05),观察组6个月生存率97.14%较对照组78.79%为高(χ^(2)=3.886,P=0.049)。结论对NSCLC合并脑转移患者采取全身化疗加用PD-1抑制剂联合颅脑放疗,可显著改善肿瘤标志物,用药安全性较好,6个月生存率较高,值得推广。Objective To investigate the clinical effect of programmed death protein-1(PD-1)inhibitor combined with craniocerebral radiotherapy in the treatment of non-small cell lung cancer(NSCLC)with brain metastases.Methods A total of 68 patients with brain metastases of NSCLC admitted to the 960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from September 2021 to May 2023 were selected and divided into two groups according to different treatment methods,among which the control group(n=33)was treated with systemic chemotherapy combined with cranial radiotherapy,and the observation group(n=35)was treated with systemic chemotherapy combined with cranial radiotherapy plus PD-1 inhibitors,and the two groups were treated with 4 courses of treatment,and the efficacy of the two groups was compared.Results The objective response rate(ORR)in the observation group was higher than that in the control group(P<0.05).After 4 courses of treatment,the level of tumor markers in the observation group was better than that in the control group(P<0.05).The incidence of adverse reactions between the two groups was not significantly different(P>0.05),and the 6-month survival rate of the observation group was 97.14%,higher than that of the control group(78.79%)(χ~2=3.886,P=0.049).Conclusion Systemic chemotherapy plus PD-1 inhibitor combined with craniocerebral radiotherapy for NSCLC patients with brain metastases can significantly improve tumor markers,with good drug safety and high 6-month survival rate,which is worthy of promotion.

关 键 词：程序性死亡蛋白抑制剂 颅脑放疗 非小细胞肺癌 脑转移 

分 类 号：R734.2[医药卫生—肿瘤]